randomized controlled trial
some concerns about risk of bias
Cannabidiol
300mg/day Cannabidiol plus standard of care during 14 days.
Placebo
Placebo plus standard of care during 14 days.
COVID-19 mild to moderate
Double-blind.
2 sites in Sao Paulo, Brazil.
Primary endpoint was measured with the COVID-19 Scale or the natural course of the resolution of typical clinical symptoms, and assessed on days 14, 21, and 28 after enrollment.
VERU-111, 2022 NCT04842747
sabizabulin (n=134) vs. placebo (n=70)
randomized controlled trial
some concerns about risk of bias
daily oral doses of sabizabulin 9mg for 21 days
placebo
COVID-19 mild to moderate
double-blind
27 centers, worldwide
met the prespecified superiority criterion for efficacy at the time of the interim analysis with 150 patients